P. Preusser

1.8k total citations
47 papers, 1.3k citations indexed

About

P. Preusser is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, P. Preusser has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 13 papers in Surgery. Recurrent topics in P. Preusser's work include Gastric Cancer Management and Outcomes (24 papers), Metastasis and carcinoma case studies (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). P. Preusser is often cited by papers focused on Gastric Cancer Management and Outcomes (24 papers), Metastasis and carcinoma case studies (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). P. Preusser collaborates with scholars based in Germany, United States and Switzerland. P. Preusser's co-authors include H. Wilke, W. Achterrath, Luigi Lenaz, Jochen Meyer, U. Fink, H J Meyer, A. Heinicke, H. Wilke, H. Knipp and U. Gunzer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

P. Preusser

44 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Preusser Germany 17 965 658 534 249 115 47 1.3k
Thomas Linné Sweden 7 921 1.0× 968 1.5× 668 1.3× 181 0.7× 103 0.9× 10 1.4k
Takashi Nagaie Japan 10 1.4k 1.4× 781 1.2× 643 1.2× 620 2.5× 155 1.3× 44 1.8k
Chang Hak Yoo South Korea 20 1.0k 1.0× 437 0.7× 592 1.1× 436 1.8× 139 1.2× 47 1.4k
Shinya Ueda Japan 18 728 0.8× 599 0.9× 419 0.8× 253 1.0× 302 2.6× 67 1.3k
Yasushi Mitachi Japan 9 711 0.7× 732 1.1× 295 0.6× 189 0.8× 128 1.1× 18 1.1k
Genichi Nishimura Japan 20 550 0.6× 399 0.6× 659 1.2× 315 1.3× 322 2.8× 62 1.5k
Nozomu Machida Japan 20 802 0.8× 819 1.2× 429 0.8× 251 1.0× 166 1.4× 135 1.4k
Hugo Ford United Kingdom 16 775 0.8× 723 1.1× 328 0.6× 157 0.6× 142 1.2× 32 1.1k
Yoh Isobe Japan 16 1.2k 1.2× 434 0.7× 827 1.5× 482 1.9× 181 1.6× 38 1.7k
Tadashi Nishimaki Japan 24 1.4k 1.5× 548 0.8× 1.5k 2.8× 184 0.7× 240 2.1× 105 2.2k

Countries citing papers authored by P. Preusser

Since Specialization
Citations

This map shows the geographic impact of P. Preusser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Preusser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Preusser more than expected).

Fields of papers citing papers by P. Preusser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Preusser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Preusser. The network helps show where P. Preusser may publish in the future.

Co-authorship network of co-authors of P. Preusser

This figure shows the co-authorship network connecting the top 25 collaborators of P. Preusser. A scholar is included among the top collaborators of P. Preusser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Preusser. P. Preusser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Braun, Ada, W. Achterrath, H. Wilke, et al.. (2004). New systemic frontline treatment for metastatic colorectal carcinoma. Cancer. 100(8). 1558–1577. 63 indexed citations
3.
Köhne, C.-H., Raphael Catane, B. Klein, et al.. (2003). Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. British Journal of Cancer. 89(6). 997–1001. 78 indexed citations
4.
Harstrick, A., C.-H. Köhne, Wolfgang Hiddemann, et al.. (1997). Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphon acetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. Annals of Oncology. 8(9). 917–918. 2 indexed citations
5.
Erlichman, Charles, Sean Fine, Ian G. Kerr, et al.. (1996). A Phase II Trial of 5-Fluorouracil and I-Leucovorin in Patients with Metastatic Colorectal Cancer. American Journal of Clinical Oncology. 19(1). 26–31. 7 indexed citations
6.
Wilke, H., P. Preusser, M. Stahl, et al.. (1994). Phase II Study with Folinic Acid, Etoposide, 5-Fluorouracil and Cisplatin (FLEP) for Advanced Gastric Cancer. Oncology Research and Treatment. 17(2). 154–157.
7.
Erlichman, Charles, Shai Fine, Ian G. Kerr, et al.. (1993). Experience with 5FU + L-Leucovorin. Advances in experimental medicine and biology. 339. 77–79.
8.
Harstrick, A., Carsten Bokemeyer, P. Preusser, et al.. (1992). Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemotherapy and Pharmacology. 29(4). 321–322. 16 indexed citations
9.
Schleyer, Eberhard, et al.. (1992). Pharmacokinetics and protein binding of leucovorin diastereomers. 33. 532. 1 indexed citations
10.
Stahl, M., H. Wilke, P. Preusser, et al.. (1991). Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk. Oncology Research and Treatment. 14(4). 314–318. 5 indexed citations
11.
Klein, H. O., R. Herrmann, D Hossfeld, et al.. (1990). Chemotherapie gastrointestinaler Tumoren. Oncology Research and Treatment. 13(1). 63–65. 1 indexed citations
12.
Queißer, W., P. Preusser, K. Mross, et al.. (1990). Phase II Evaluation of Carboplatin in Advanced Esophageal Carcinoma. Oncology Research and Treatment. 13(3). 190–193. 9 indexed citations
13.
Wilke, H., P. Preusser, U. Fink, et al.. (1990). High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk. Investigational New Drugs. 8(1). 65–70. 43 indexed citations
14.
Wilke, H., P. Preusser, U. Fink, et al.. (1989). Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.. Journal of Clinical Oncology. 7(9). 1318–1326. 228 indexed citations
15.
Winde, G, et al.. (1989). Duplex-Sonographie in der Diagnostik von Nierenarterienstenosen nach allogener Nierentransplantation. Langenbeck s Archives of Surgery. 374(5). 284–290. 2 indexed citations
16.
Hiddemann, Wolfgang, D. Urbanitz, P. Preusser, W. Achterrath, & Thomas Büchner. (1989). Treatment of refractory acute myeloid leukemia with mAMSA and VP 16‐213 in combination: Results of a clinical phase I/II study. Hematological Oncology. 7(4). 267–273. 5 indexed citations
17.
Wilke, H., W. Achterrath, Hans‐Joachim Schmoll, et al.. (1988). Etoposide and Split-Dose Cisplatin in Small-Cell Lung Cancer. American Journal of Clinical Oncology. 11(5). 572–578. 18 indexed citations
18.
Preusser, P., H. Wilke, W. Achterrath, et al.. (1988). Phase-II-Study with EAP (Etoposide, Adriamycin, Cis- Platinum) in Patients with Primary Inoperable Gastric Cancer and Advanced Disease. Recent results in cancer research. 110. 198–206. 5 indexed citations
19.
Hiddemann, Wolfgang, et al.. (1985). AMSA/Etoposid (VP 16-213) Eine Phase I/II Studie bei refraktärer akuter myeloischer Leukämie. Oncology Research and Treatment. 8(3). 181–184. 3 indexed citations
20.
Hiddemann, Wolfgang, W. Achterrath, D. Urbanitz, et al.. (1984). Kombinationstherapie mit AMSA und Etoposid (VP 16-213) bei refraktärer akuter myeloischer Leukämie:Eine Phase-I-Studie. Oncology Research and Treatment. 7(4). 214–216. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Linné Breakdown of academic impact, for papers by Takashi Nagaie Breakdown of academic impact, for papers by Chang Hak Yoo Breakdown of academic impact, for papers by Shinya Ueda Breakdown of academic impact, for papers by Yasushi Mitachi Breakdown of academic impact, for papers by Genichi Nishimura Breakdown of academic impact, for papers by Nozomu Machida Breakdown of academic impact, for papers by Hugo Ford Breakdown of academic impact, for papers by Yoh Isobe Breakdown of academic impact, for papers by Tadashi Nishimaki
Rankless by CCL
2026